Q3 Revenue Jumps 21% to $117.6M, Topping Consensus; Guidance Tightened
PHAR is trading near its 52-week low of $9.11 (4.8% above the low).
Summary
Pharming pre-announced Q3 2026 revenue of roughly $117.6M, up 21% from $97.3M a year ago and above analyst consensus, with opex of about $74.6M flat year-over-year. RUCONEST brought in $93.8M, up 14% YoY and 30% sequentially on U.S. demand recovery and channel restocking at a single specialty pharmacy; Joenja added $23.8M, up 58% YoY on U.S. patient growth plus Germany and Japan launches. Management tightened FY2026 revenue guidance to $380M-$390M from $375M-$395M and cut opex guidance to $310M-$315M, and moved the full Q3 report up to October 27 from November 5. This is the first sign of stabilization after the July 30 guidance cut and the surprise CEO exit on September 29, and it lands with the stock near its 52-week low. Watch the November 2026 CVID Phase II topline for the broader leniolisib opportunity.
At the time of this announcement, PHAR was trading at $9.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $676.2M. The 52-week trading range was $9.11 to $21.34. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.